<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649636</url>
  </required_header>
  <id_info>
    <org_study_id>FLUO-0603</org_study_id>
    <nct_id>NCT00649636</nct_id>
  </id_info>
  <brief_title>Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg</brief_title>
  <official_title>Single-Dose Fasting Bioequivalence Study of Fluoxetine Capsules (40 mg; Mylan) and Prozac Pulvules (40 mg; Dista) in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the bioequivalence of Mylan's fluoxetine&#xD;
      hydrochloride 40 mg capsules to Dista's Prozac 40 mg pulvules following a single, oral 40 mg&#xD;
      (1 x 40 mg) dose administration under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
    <time_frame>within 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluoxetine Capsules 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prozac Pulvules 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine Capsules 40 mg</intervention_name>
    <description>40mg, single dose fasting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prozac Pulvules 40 mg</intervention_name>
    <description>40mg, single dose fasting</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 years and older.&#xD;
&#xD;
          2. Sex: Male and/or non-pregnant, non-lactating female. a. Women of childbearing&#xD;
             potential must have negative serum beta human chorionic gonadotropin (b-HCG) pregnancy&#xD;
             tests performed within 21 days prior to the start of the study and on the evening&#xD;
             prior to each dose administration. If dosing is scheduled on weekends, the HCG&#xD;
             pregnancy test should be given within 48 hours prior to dosing of each study period.&#xD;
             An additional serum (b-HCG) pregnancy test will be performed upon completion of the&#xD;
             study. b. Women of childbearing potential must practice abstinence or be using an&#xD;
             acceptable form of contraception throughout the duration of the study. No hormonal&#xD;
             contraceptives or hormone replacement therapy are permitted in this study. Acceptable&#xD;
             forms of contraception include the following: 1) intrauterine device in place for at&#xD;
             least 3 months prior to the start of the study and remaining in place during the study&#xD;
             period, or 2) barrier methods containing or used in conjunction with a spermicidal&#xD;
             agent, or 3) surgical sterility (tubal ligation, oophorectomy or hysterectomy) or&#xD;
             postmenopausal accompanied with a documented postmenopausal course of at least one&#xD;
             year. c. Women will not be considered of childbearing potential if one of the&#xD;
             following is reported and documented on the medical history: 1) postmenopausal with an&#xD;
             absence of menses for at least one 2) bilateral oophorectomy with or without a&#xD;
             hysterectomy and 3) total hysterectomy d. During the course of the study, from study&#xD;
             screen until study exit, all men and women of childbearing potential must use a&#xD;
             spermicide-containing barrier method of contraception in addition to their current&#xD;
             contraceptive device. This requirement should be documented in the informed consent&#xD;
             form.&#xD;
&#xD;
          3. Weight:At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women with all&#xD;
             subjects having a Body Mass Index (BMI) less than or equal to 30 but greater than or&#xD;
             equal to 19. (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).&#xD;
&#xD;
          4. All subjects should be judged normal and healthy during a pre-study medical evaluation&#xD;
             (physical examination, laboratory evaluation, Hepatitis B and Hepatitis C tests, HIV&#xD;
             test, 12-lead ECG, and urine drug screen including amphetamine, barbiturates,&#xD;
             benzodiazepines, cannabinoid, cocaine, opiates, phencyclidine, and methadone)&#xD;
             performed within 21 days of the initial dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Institutionalized subjects will not be used.&#xD;
&#xD;
          2. Social Habits: a. Use of any tobacco products within one year prior to dosing. b.&#xD;
             Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within&#xD;
             the 48 hours prior to the initial dose of study medication. c. Ingestion of any&#xD;
             vitamins or herbal products within 7 days prior to the initial dose of the study&#xD;
             medication. d. Any recent, significant change in dietary or exercise habits. e. A&#xD;
             positive test for any drug included in the urine drug screen. f. History of drug&#xD;
             and/or alcohol abuse.&#xD;
&#xD;
          3. Medications: a. Use of any prescription or over-the-counter (OTC) medications within&#xD;
             the 14 days prior to the initial dose of study medication, especially any monoamine&#xD;
             oxidase inhibitor (MAOI). b. Use of any hormonal contraceptives and hormone&#xD;
             replacement therapy within 3 months prior to study medication dosing. c. Use of any&#xD;
             medication known to alter hepatic enzyme activity within 35 days prior to the initial&#xD;
             dose of study medication.&#xD;
&#xD;
          4. Diseases: a. History of any significant cardiovascular, hepatic, renal, pulmonary,&#xD;
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic&#xD;
             disease. b. Acute illness at the time of either the pre-study medical evaluation or&#xD;
             dosing. c. A positive HIV, Hepatitis B, or Hepatitis C test. d. History of seizures or&#xD;
             any psychiatric disorders.&#xD;
&#xD;
          5. Abnormal and clinically significant laboratory test results: a. Clinically significant&#xD;
             deviation from the Guide to Clinically Relevant Abnormalities (See Part II&#xD;
             ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS). b. Abnormal and clinically&#xD;
             relevant ECG tracing.&#xD;
&#xD;
          6. Donation or loss of a significant volume of blood or plasma (&gt; 450 mL) within 28 days&#xD;
             prior to the initial dose of study medication.&#xD;
&#xD;
          7. Subjects who have received an investigational drug within 30 days prior to the initial&#xD;
             dose of study medication.&#xD;
&#xD;
          8. Allergy or hypersensitivity to fluoxetine, any of the inactive ingredients, or other&#xD;
             related products.&#xD;
&#xD;
          9. History of difficulties in swallowing, or any gastrointestinal disease which could&#xD;
             affect the drug absorption.&#xD;
&#xD;
         10. Consumption of grapefruit or grapefruit containing products within 7 days of drug&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Carlson, Pharm. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Will Sullvan, Global Head of Product Risk and Safety Management</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

